Lantus Manufacturer

Fda Approves New Basal Insulin Toujeo

The FDA has approved Sanofi’s once-daily basal insulin, but will it compete with Sanofi’s own Lantus? Quick Hits Sanofi, which has been bracing for increased competition for Lantus, has won the race to bring a new basal insulin to the marketplace. This week, the drug manufacturer announced the FDA has approved Toujeo, its new once-daily long-acting basal insulin. The new insulin is expected to go on sale in the U.S. by the start of the second quarter of this year. Studies found that Toujeo’s overall ability to control blood sugar levels matched that of Lantus. It also proved more effective at controlling nighttime hypoglycemia, according to a Bloomberg report. The biggest difference between the two basal insulins is that while Lantus contains 100 units/mL, Toujeo is more concentrated and triples Lantus’ capacity, yielding 300 units/mL. While Lantus is suitable for people with diabetes who are age 6 and up, Toujeo is only approved to treat patients who are 18 years and older. Interestingly, pharmaceutical market watchers weren’t overwhelmed by the news of Toujeo’s approval, according to a report in Fierce Pharma. One market analyst predicted that many Lantus users will not switch over to Toujeo because they will not see enough difference between the two insulins. Since Sanofi owns both products, you would think that would be good news, but Sanofi’s profit margin for Lantus has come under threat. Insurance payors are demanding a cut in the price of Lantus in 2015. Also, there is the pending threat of generic versions of Lantus flooding the marketplace. It’s believed that Sanofi must establish a strong foothold with Toujeo in the basal insulin marketplace if it is to maintain its profit margin. UPDATE – 3/5/15 – EU regulators have given Toujeo the green Continue reading >>

Pay No More Than $10

Our database contains 2 offers for Lantus: This is a discount offer provided by the manufacturer of Lantus. Click the link below to visit their website for additional information or to sign up for the offer. Manufacturer Coupon 2018 Lantus Sign up for the Lantus® Savings Card and you'll pay no more than $10 per Lantus® SoloSTAR® prescription for the program duration. The Sanofi Rx Savings Card carries a maximum savings up to $500 per prescription for all patients who are enrolled in a commercial insurance plan and $100 per prescription for patients not enrolled in a commercial insurance plan. Offer provided by: Sanofi NOTE: This is an offer provided by the manufacturer. Save Up To 50% Off Retail PriceLantus Discount Drug Coupon (Free – No Membership Fees) This Free drug coupon has No Membership Fees and provides access to wholesale Lantus prices. Over 68,000 participating pharmacies accept this Reusable drug coupon. Note: prescription is required for savings. Continue reading >>

Easd: Additional Evidence Showed Abasaglar® (insulin Glargine) Provided Safety And Efficacy Similar To Lantus®

The subgroup of patients previously treated with Lantus had significant reductions in average blood glucose levels (HbA1c) from baseline when they were randomised to either ABASAGLAR or Lantus. Similar to the total study population, the analyses showed no significant differences in HbA1c reduction from baseline to 52 weeks in type 1 patients (-0.28 percent vs. -0.26 percent) and to 24 weeks in type 2 patients (-1.02 percent vs. -1.01 percent) with ABASAGLAR and Lantus treatment, respectively. Results also showed no significant differences between the two treatments in key secondary efficacy and safety measures, including percentage of patients reaching target HbA1c levels, total and nocturnal hypoglycaemia rates and incidence of treatment-related adverse events. Statistical differences were seen in weight change, incidence of detectable antibodies and incidence of serious adverse events; however, these differences were not observed in the total study populations. Further, these results were not consistently observed across both studies and did not indicate any clinically meaningful treatment differences. "These secondary analyses are important because they provide additional perspectives on how ABASAGLAR works in people with diabetes, regardless of prior insulin glargine treatment," said David Kendall, MD, vice president, Medical Affairs, Lilly Diabetes. "These data provide important additional evidence for the similarity of ABASAGLAR to Lantus in people with type 1 and type 2 diabetes and provide physicians further information on this new treatment option." ABASAGLAR® was first granted approval by the European Commission in September 2014, marking the first biosimilar insulin approval in the European Union. As of September 2015, ABASAGLAR has been commercially launche Continue reading >>

How To Find A Lantus Coupon

It looks like this page may be out of date. Please visit NerdWallet’s health hub for our latest content. Diabetics don’t have much of a choice when it comes to taking their insulin, and the costs can be very high, so a Lantus coupon can be invaluable. Paired with diabetic supplies like syringes and blood glucose testing equipment, diabetes is an expensive disease. But with a little bit of information and some resourcefulness, you may be able to save on your monthly prescriptions. Lantus is a long-acting insulin made by Sanofi-Aventis and prescribed to both Type 1 and Type 2 diabetics. Diabetics are unable to naturally produce or use insulin like most people, so they take injections of synthetic insulin to help regulate their blood sugar. Generic Lantus At this time, there is no generic form of Lantus available. However, that may soon change. The patents protecting Lantus from cheaper generic alternatives expired in February 2015, so less expensive forms of the drug may be coming. When this happens, opting for generic will likely be the best way to save on Lantus, and because of FDA requirements, you don’t have to worry about the generic version being less effective or less safe. Although some people avoid buying generics because they are afraid they won’t work as well as the name brands, those fears are largely unfounded. Lantus coupons from the manufacturer One carton of Lantus can cost close to $400 without insurance, according to GoodRx.com, though Lantus may very well be part of your insurance formulary. Currently, the maker of the drug offers a Lantus Savings Card. According to its website, the card can reduce your prescription cost to no more than $25. However, it also says there is a maximum benefit of $100 off each prescription for the duration of the pr Continue reading >>

(insulin Glargine Injection) Solution For Subcutaneous Injection

2. DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions Visually inspect LANTUS vials and SoloStar prefilled pens for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles. 2.2 General Dosing Instructions 2.3 Initiation of LANTUS Therapy 2.4 Changing to LANTUS from Other Insulin Therapies If changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with LANTUS, a change in the dose of the basal insulin may be required and the amount and timing of the shorter-acting insulins and doses of any oral anti-diabetic drugs may be needed to be adjusted. If changing patients from once-daily NPH insulin to once-daily LANTUS, the recommended initial LANTUS dose is the same as the dose of NPH that is being discontinued. 5. WARNINGS AND PRECAUTIONS 5.1 Never Share a LANTUS SoloStar Prefilled Pen, Syringe, or Needle between Patients LANTUS SoloStar prefilled pens must never be shared between patients, even if the needle is changed. Patients using LANTUS vials must never reuse or share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions (5.3)] or hyperglycemia. These changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant oral and anti-diabetic products may be needed. 5.3 Hypoglycemia Hypoglycemia is the most common adverse Continue reading >>

(insulin Glargine Injection) 300 Units/ml

If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at 1-800-633-1610. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment. Continue reading >>

Lantus Coupon 5604

This voucher is for up to a 30-day supply of Lantus (insulin glargine injection) 100 Units/mL. After your physician provides you with a valid, signed prescription, take the prescription and this voucher to any participating pharmacy to receive your 30-day supply of Lantus. Be sure to follow all instructions provided by your physician. More information about Lantus will come with your prescription. By redeeming this voucher, you agree that you understand and will abide by the terms and conditions of this offer. Redeem one time for product only when accompanied by a valid, signed prescription for Lantus (insulin glargine injection) 100 Units/mL. Please submit claim to McKesson Corporation using BIN #610524. The information printed above should be used when submitting for reimbursement. For questions regarding McKesson Corporation processing, please call the Help Desk at: 1-800-657-7613. VOUCHER CAN ONLY BE APPLIED TO A PRESCRIPTION OF LANTUS. Valid for the duration of the program. This voucher is valid only for the patient whose name appears on the prescription for Lantus, and is limited to 1 free trial voucher redemption per person for the duration of the program. This offer is not valid for patients who have previously redeemed a trial voucher. This voucher may not be sold, purchased or traded, or offered for sale, purchase or trade, or counterfeited. Void where prohibited by law, taxed or restricted. This offer available only in the USA. Product dispensed as sample pursuant to terms of voucher shall not be submitted to any third party payer, public or private, (e.g., private insurance, Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program), for reimbursement. Offer cannot be combined with any o Continue reading >>

Sanofi Lantus Solostar Pen Assembly Plant, Yizhuang, Beijing

Christopher Viehbacher, the CEO of Sanofi, announced the cartridge aseptic production line at the plant in May 2012. Image courtesy of Sanofi. The Beijing plant of Sanofi has a design capacity of 48 million Lantus SoloSTAR insulin pens each year. Image courtesy of Sanofi. Groundbreaking of Sanofi’s Lantus SoloSTAR assembly and packaging plant in Beijing. Image courtesy of Sanofi. Sanofi China opened a new assembling and packaging facility for prefilled insulin devices in Beijing, China, in May 2012. The facility will produce the SoloSTAR insulin injection pens prefilled with Lantus, the company’s insulin drug. Sanofi China looks after the Chinese operations of the globally diversified healthcare company Sanofi. The plant will help Sanofi serve diabetics in China and other Asian countries. During the plant’s inauguration ceremony in May 2012, the company announced the addition of an aseptic production line for cartridges at the plant. Sanofi’s Chinese manufacturing sites and production Sanofi built the new plant in Beijing in its attempt to increase production base in China. The company operates six manufacturing sites in China, including one plant each in Beijing, Shenzhen, Tangshan and Nanchang, and two plants in Hangzhou. The Beijing plant was announced three years ago, in 2009. In April 2009 Sanofi signed an agreement with Beijing e-Town International Investment to set up a plant within the Beijing Economic-Technological Development Area (BDA). Phased construction of the pen assembling facility The Beijing manufacturing facility is a $90m project for Sanofi. It is being built in two phases. The assembly and packaging plant formed the first phase of the project. The second phase will involve addition of the cartridge aseptic production line. Transport infrastr Continue reading >>

Insulin

Indication BASAGLAR is a long-acting insulin used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. Limitation of Use BASAGLAR is not for treating diabetic ketoacidosis. Important Safety Information Do not take BASAGLAR during episodes of low blood sugar or if you are allergic to insulin glargine or any of the ingredients in BASAGLAR. Do NOT reuse needles or share insulin pens, even if the needle has been changed. Before starting BASAGLAR, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant, or if you are breastfeeding or planning to breastfeed. BASAGLAR should be taken once a day at the same time every day. Test your blood sugar levels while using insulin. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. The most common side effect of insulin, including BASAGLAR, is low blood sugar (hypoglycemia), which may be serious and life threatening. Signs and symptoms may include dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood change, or hunger. Do NOT dilute or mix BASAGLAR with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. BASAGLAR must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection. BASAGLAR may cause serious side effects that can lead to death, such as severe allergic reactions. Get emergency help if you have: Heart fa Continue reading >>

(insulin Glargine Injection) 100 Units/ml?

Prescription Lantus® is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. Do not use Lantus® to treat diabetic ketoacidosis. Do not take Lantus® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus®. Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles. Before starting Lantus®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed. Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus®. Your treatment with TZDs and Lantus® may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including: Sudden weight gain Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements. Lantus® should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar Continue reading >>

Lantus Prices, Coupons And Patient Assistance Programs

Lantus (insulin glargine) is a member of the insulin drug class and is commonly used for Diabetes - Type 1 and Diabetes - Type 2. Lantus Prices This Lantus price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies. The cost for Lantus subcutaneous solution (100 units/mL) is around $276 for a supply of 10 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. Lantus is available as a brand name drug only, a generic version is not yet available. For more information, read about generic Lantus availability. Subcutaneous Solution Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee. Drugs.com Printable Discount Card Print Now The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions. Please note: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 63,000 pharmacies nationwide. Lantus Coupons and Rebates Lantus offers may be in the form of a printable coupon, rebate, savings card, trial offer, or free samples. Some offers may be printed right from a website, others require registration, completing a questionnaire, or obtaining a sample from the doctor's office. Sanofi Rx Savings Card for Lantus: Eligible patients may pay $0 copay on each of up to 12 prescriptions; for additional information contact the program at 800-981-2491. Applies to: Lantus SoloSTAR Pen Number of uses: 12 times Continue reading >>

Insulin Glargine

Insulin glargine, marketed under the names Lantus, among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert). Pharmacokinetically, it resembles basal insulin secretion of non-diabetic pancreatic beta cells. Sometimes, in type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulin—type 1 diabetes, depleted type 2 (in some cases) or latent autoimmune diabetes of adults in late stage—insulin glargine needs the support of fast acting insulin taken with food to reduce the effect of prandially derived glucose. Medical uses[edit] The long-acting insulin class, which includes insulin glargine, do not appear much better than neutral protamine Hagedorn (NPH) insulin but have a significantly greater cost making them, as of 2010, not cost effective.[1] It is unclear if there is a difference in hypoglycemia and not enough data to determine any differences with respect to long term outcomes.[2] Mixing with other insulins[edit] Unlike some other longer-acting insulins, glargine must not be diluted or mixed with other insulin or solution in the same syringe.[3] However, this restriction has been questioned.[4] Adverse effects[edit] Cancer[edit] As of 2012 tentative evidence shows no association between insulin glargine and cancer.[5] Previous studies had raised concerns.[6] Pharmacology[edit] Mechanism of action[edit] Insulin glargine has a substitution of glycine for Continue reading >>

How You Can Get Your Lantus And Apidra Through The Sanofi Patient Connection Program Absolutely Free

As part of our series on Diabetes, we are discussing Sanfi Aventis medications available to the uninsured through the Sanofi Patient Connection Program. Qualifying applicants receive free 90 day supplies of their Sanofi Aventis medications delivered directly to their doctor’s office. This program offers assistance with Apidra Vials and SoloStar Pens and Lantus Vials and SoloStar Pens. The Sanofi Patient Connection Program is available to uninsured Americans whose gross household income falls below 250% of the Federal Poverty Level. There are some exceptions for patients who are in the Medicare Part D donut hole and some Medicare eligible patients who have been denied Low Income Subsidy and Medicaid assistance. This program requires new applicants to submit supporting documents, called Proof of Income, or POI for short, to verify that your household income is below 250% of the Federal Poverty Level. The Sanofi Patient Connection program will either tax documentation or current proof of household income such as paycheck stubs, Social Security Award Letters, Unemployment Statements and even bank statements. If you are submitting current proof of income, be sure that you turn in your most recent months’ worth so that the program can get a clear understanding of your financial situation. If your household currently has zero income, you will need to submit your tax documentation. If you did not file taxes, a 4506-T Verification of Non-Filing Form can be submitted to the IRS and the form they return to you submitted to the PAP. For More information about what to send in as Proof Of Income, click here. If your tax documents show that your household income was over 250% of the Federal Poverty Level, but there has been a change and your current gross household income is below Continue reading >>

Sanofi Patient Assistance Connection & Application Form

Connecting eligible patients to medication at no cost Sanofi Patient Connection can provide medication at no cost if you meet program eligibility requirements. This component of the program is made possible through the Sanofi Foundation for North America. In order to be eligible for the program, you must meet the following requirements: You must be a U.S. citizen or resident and be under the care of a licensed healthcare provider authorized to prescribe, dispense and administer medicine in the U.S. You must have no insurance coverage or access to the prescribed product or treatment via your insurance You must not be eligible for Medicare or Medicaid. If you are enrolled in Medicare Part D, view eligibility criteria here . You must meet the following financial criteria: Annual household income of 250% of the current Federal Poverty Level for all non-oncology/non-hematology products. View Financial Eligibility information . Annual household income of 500% of the current Federal Poverty Level for all non-oncology/non-hematology products. View Financial Eligibility information . Continue reading >>

Lantus Manufacturing Problem?

Diabetes Forum The Global Diabetes Community Find support, ask questions and share your experiences. Join the community I went to get my lantus from boots today and they could only give me 2 pens (script was for 2 boxes of 5 pens). They had more but needed to give them to someone else. Apparantly there is a manufacturing problem and they don't know when they can get any more. Other chemists in the area have same problem. Has anyone else heard this? I can't imagine they would run out of a drug like lantus which thousands of diabetics rely on to stay alive. I have enough to last me a couple of weeks now so hope they can sort it out before then but what would happen if they couldn't? I'm a dispenser in a pharmacy and yes there there seems to be an issue with some of the Lantus pens. Lantus Solostar pens seem to be the only ones available now (don't know if that's permanent or if the others will reappear), but Lantus penfill cartridges are also still available. Don't panic - ask your doc if you can have the Solostar pens or the cartridges to go into a reusable pen Ooh, have just remembered the message we got at work on the Lantus Opticlik and Optiset was 'discontinued'. But the advantage of the Solostar pens is that they can be dialled up in increments of one instead of two. Am I right in thinking the other pens were in steps of 2? And if you end up using cartridges in reusable pens, you can get those pens which dial up in half unit increments, which is great for fine tuning dose changes. Hope that helps. I'm a dispenser in a pharmacy and yes there there seems to be an issue with some of the Lantus pens. Lantus Solostar pens seem to be the only ones available now (don't know if that's permanent or if the others will reappear), but Lantus penfill cartridges are also still a Continue reading >>